Severe hypercalcemia in a patient with chronic lymphocytic leukemia and non-small cell lung carcinoma
暂无分享,去创建一个
[1] J. Bergler-Klein. Real-Life Insight Into Ibrutinib Cardiovascular Events: Defining the Loose Ends. , 2019, Journal of the American College of Cardiology.
[2] Yanwei Xing,et al. Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium. , 2019, Heart rhythm.
[3] L. Larocca,et al. Clinical, pathological, and biological characterization of Richter syndrome developing after ibrutinib treatment for relapsed chronic lymphocytic leukemia , 2018, Hematological oncology.
[4] N. Komatsu,et al. Usage and Distribution for Commercial Purposes Requires Written Permission. Richter's Syndrome with Hypercalcemia Induced by Tumor-associated Production of Parathyroid Hormone-related Peptide , 2022 .
[5] E. Koutroumpakis,et al. Symptomatic Hypercalcemia in a Patient with B-cell Chronic Lymphocytic Leukemia - A Case Report and Review of the Literature. , 2016, In vivo.
[6] A. Liede,et al. Prevalence of hypercalcemia among cancer patients in the United States , 2016, Cancer medicine.
[7] T. Kipps,et al. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. , 2015, The New England journal of medicine.
[8] A. Liede,et al. Prevalence of hypercalcemia of malignancy among cancer patients in the UK: analysis of the Clinical Practice Research Datalink database. , 2015, Cancer epidemiology.
[9] A. Mirrakhimov. Hypercalcemia of Malignancy: An Update on Pathogenesis and Management , 2015, North American journal of medical sciences.
[10] J. Jones,et al. PTHrP-Induced Refractory Malignant Hypercalcemia in a Patient With Chronic Lymphocytic Leukemia Responding to Denosumab. , 2015, Clinical lymphoma, myeloma & leukemia.
[11] A. Neugut,et al. Quality and Outcomes of Treatment of Hypercalcemia of Malignancy , 2015, Cancer investigation.
[12] S. Minisola,et al. The diagnosis and management of hypercalcaemia , 2015, BMJ : British Medical Journal.
[13] D. McLeod,et al. PTHrP-mediated hypercalcemia: causes and survival in 138 patients. , 2015, The Journal of clinical endocrinology and metabolism.
[14] A. Akçay,et al. The coexistence of renal cell carcinoma and diffuse large B-cell lymphoma with hypercalcemic crisis as the initial presentation. , 2014, Endocrine Regulations.
[15] R. Jain,et al. Denosumab for Patients With Persistent or Relapsed Hypercalcemia of Malignancy Despite Recent Bisphosphonate Treatment , 2013, Journal of the National Cancer Institute.
[16] W. Schmiegel,et al. A Rare Case of Chronic Lymphocytic Leukemia with Hypercalcemia Induced by Elevated Parathyroid Hormone-Related Peptides , 2010, Acta Haematologica.
[17] D. Black,et al. Clinical Practice. Postmenopausal Osteoporosis. , 2005, The New England journal of medicine.
[18] P. Kostenuik,et al. The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. , 2005, Endocrinology.
[19] A. F. Stewart. Hypercalcemia Associated with Cancer , 2005 .
[20] G. Mills,et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Antoine Martin,et al. Hypercalcemia may indicate Richter's syndrome , 1997, Cancer.
[22] D. Meseure,et al. Hypercalcaemia in B cell chronic lymphocytic leukaemia , 1994, British journal of haematology.
[23] B. Schöttker,et al. Parathyroid-hormone-related-protein-associated hypercalcemia in a patient with CLL-type low-grade leukemic B-cell lymphoma. , 2006, Haematologica.
[24] P. Pauwels,et al. Parathyroid hormone-related protein (PTH-rP)-associated hypercalcemia in a patient with an atypical chronic lymphocytic leukemia. , 1999, The Netherlands journal of medicine.